Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290315 · ClinicalTrials.gov registry record · Phase 2
Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
A Phase 2 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT01290315 is a Phase 2 study that has completed, run by American Regent. The registered enrollment target is 49 participants.
The verdict
NCT01290315, a Phase 2 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to compare safety and the oxidative stress potential of two doses of an investigational IV iron, ferric carboxymaltose (FCM), compared to an equal single dose of IV iron sucrose or IV iron dextran in the treatment of Iron Deficiency Anemia (IDA) in female subjects.
Interventions
- DRUG Ferric Carboxymaltose (FCM)
- DRUG Iron Sucrose / Iron Dextran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290315
The ClinicalTrials.gov registry entry for NCT01290315 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferric Carboxymaltose (FCM) is the first listed.
NCT01290315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290315 about?
NCT01290315 is a clinical study titled "Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women". The purpose of this study is to compare safety and the oxidative stress potential of two doses of an investigational IV iron, ferric carboxymaltose (FCM), compared to an equal single dose of IV iron sucrose or IV iron dextran in the treatment of Iron Deficiency Anemia (IDA) in female subjects.
What is the current status of trial NCT01290315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2009-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01290315?
The interventions under investigation include: Ferric Carboxymaltose (FCM) (DRUG), Iron Sucrose / Iron Dextran (DRUG).
Who is sponsoring clinical trial NCT01290315?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.